Livagen
Also known as: Peptídeo hepático
Molecular Identifiers
Overview
Hepatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in hepatocytes and supports liver function, including detoxification processes. Used in short cycles for hepatic protection and regeneration.
The main clinical interest around Livagen is hepatic function support: regulation of gene expression in hepatocytes, normalization of protein and lipid metabolism, and modulation of detoxification processes. It is frequently used in "bioregulation" strategies for mild hepatopathies, steatosis, or after exposure to hepatotoxins.
Livagen currently has no regulatory approval from any Western agency (FDA, EMA, ANVISA). It is most often dispensed by compounding pharmacies as off-label use, in short 10-20 day cycles repeated 2 to 4 times a year. It belongs to the family of short bioregulatory peptides developed in Russia by Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology, which since the 1970s has characterized tissue-specific tetrapeptides derived from organ extracts.
Within the Khavinson family, Livagen is most often compared to Ovagen, another short peptide tied to the hepatic axis: Livagen is described with a tighter focus on the hepatocyte and on hepatic protein/lipid metabolism, while Ovagen is presented as extending the action toward the gastrointestinal tract and intestinal mucosa. All of this comparative literature is largely Russian and preclinical.
KEDA Lys-Glu-Asp-Ala Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in hepatocytes
- Support for hepatic function and detoxification capacity
- Normalization of hepatic protein and lipid metabolism
- Modulation of hepatic tissue regeneration
- Bioregulatory effect on hepatobiliary function
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Very stable as a tetrapeptide. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Livagen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Livagen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals